Abstract
Although strong genetic determinants of multiple sclerosis (MS) exist, the findings of migration studies support a role for environmental factors in this disease. Through rigorous epidemiological investigation, Epstein–Barr virus infection, vitamin D nutrition and cigarette smoking have been identified as likely causal factors in MS. In this Review, the strength of this evidence is discussed, as well as the potential biological mechanisms underlying the associations between MS and environmental, lifestyle and dietary factors. Both vitamin D nutrition and cigarette smoking are modifiable; as such, increasing vitamin D levels and smoking avoidance have the potential to substantially reduce MS risk and influence disease progression. Improving our understanding of the environmental factors involved in MS will lead to new and more-effective approaches to prevent this disease.
Key Points
-
The aetiology of multiple sclerosis (MS) is multifactorial, with both genetic and environmental factors contributing to the risk of disease
-
Strong evidence supports a causal role for Epstein–Barr virus (EBV) infection in the initiation of MS
-
Primary infection with EBV and a history of infectious mononucleosis increase an individual's risk of MS, with elevation of antibody titres to EBV nuclear antigen being observed before disease onset
-
Longitudinal studies of supplementary vitamin D intake and pre-onset serum levels of 25-hydroxyvitamin D support a protective effect of vitamin D on MS risk
-
Cigarette smoking has been associated with an increased risk of MS in men and women, and changes in smoking patterns may partially explain the increasing female:male ratio in MS
-
Our understanding of how EBV infection, vitamin D metabolism, and cigarette smoking influence MS risk are limited, and further studies are required
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
MacMahon, B. & Trichopoulos, D. Epidemiology: Principles and Methods, 2nd edn (Little, Brown & Co, Boston, 1996).
Czeizel, A. E. & Dudas, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327, 1832–1835 (1992).
Dwyer, T., Ponsonby, A. L., Blizzard, L., Newman, N. M. & Cochrane, J. A. The contribution of changes in the prevalence of prone sleeping position to the decline in sudden infant death syndrome in Tasmania. JAMA 273, 783–789 (1995).
McMahon, B. J. et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54, 801–807 (2011).
Koch-Henriksen, N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult. Scler. 5, 293–296 (1999).
Mayr, W. T. et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology 61, 1373–1377 (2003).
Compston, A. & Coles, A. Multiple sclerosis. Lancet 359, 1221–1231 (2002).
Kurtzke, J. F., Beebe, G. W. & Norman, J. E. Epidemiology of multiple sclerosis in US veterans: 1. Race, sex, and geographic distribution. Neurology 29, 1228–1235 (1979).
Wallin, M. T., Page, W. F. & Kurtzke, J. F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55, 65–71 (2004).
Wallin, M. T. et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 135, 1778–1785 (2012).
Hansen, T. et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 11, 504–510 (2005).
Willer, C. J., Dyment, D. A., Risch, N. J., Sadovnick, A. D. & Ebers, G. C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl Acad. Sci. USA 100, 12877–12882 (2003).
Ebers, G. C., Sadovnick, A. D. & Risch, N. J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377, 150–151 (1995).
Schmidt, H., Williamson, D. & Ashley-Koch, A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 165, 1097–1109 (2007).
Sadovnick, A. D. Genetic background of multiple sclerosis. Autoimmun. Rev. 11, 163–166 (2012).
Marrosu, M. G. et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am. J. Hum. Genet. 61, 454–457 (1997).
Haines, J. L. et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum. Mol. Genet. 7, 1229–1234 (1998).
Lincoln, M. R. et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc. Natl Acad. Sci. USA 106, 7542–7547 (2009).
Patsopoulos, N. A. & de Bakker, P. I. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 70, 897–912 (2011).
Ramagopalan, S. V. et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70, 881–886 (2011).
Alonso, A., Hernán, M. A. & Ascherio, A. Allergy, family history of autoimmune diseases, and the risk of multiple sclerosis. Acta Neurol. Scand. 117, 15–20 (2008).
Zorzon, M. et al. Risk factors of multiple sclerosis: a case–control study. Neurol. Sci. 24, 242–247 (2003).
Acheson, E. D., Bachrach, C. A. & Wright, F. M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr. Scand. 147, 132–147 (1960).
Gale, C. R. & Martyn, C. N. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425–448 (1995).
McLeod, J. G., Hammond, S. R. & Kurtzke, J. F. Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J. Neurol. 258, 1140–1149 (2011).
Kurtzke, J. F., Beebe, G. W. & Norman, J. E. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 35, 672–678 (1985).
Elian, M. & Dean, G. Motor neuron disease and multiple sclerosis among immigrants to England from the Indian subcontinent, the Caribbean, and East and West Africa. J. Neurol. Neurosurg. Psychiatry 56, 454–457 (1993).
Cabre, P. et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 128, 2899–2910 (2005).
Hernán, M. A., Olek, M. J. & Ascherio, A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 53, 1711–1718 (1999).
Koch-Henriksen, N. & Sorensen, P. S. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? J. Neurol. Sci. 311, 58–63 (2011).
Alonso, A. & Hernán, M. A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71, 129–135 (2008).
Simpson, S. Jr, Blizzard, L., Otahal, P., Van der Mei, I. & Taylor, B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82, 1132–1141 (2011).
Taylor, B. V. et al. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult. Scler. 16, 398–405 (2010).
Henle, W. & Henle, G. in The Epstein–Barr Virus (eds Epstein, M. A. & Achong, B. G.) 61–78 (Springer, Berlin Heidelberg, New York, 1979).
Takeuchi, K. et al. Prevalence of Epstein–Barr virus in Japan: trends and future prediction. Pathol. Int. 56, 112–116 (2006).
Hallee, T. J., Evans, A. S., Niederman, J. C., Brooks, C. M. & Voegtly, J. H. Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J. Biol. Med. 3, 182–195 (1974).
Warner, H. B. & Carp, R. I. Multiple sclerosis and Epstein–Barr virus. Lancet 2, 1290 (1981).
Thacker, E. L., Mirzaei, F. & Ascherio, A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499–503 (2006).
Bach, J. F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911–920 (2002).
Ascherio, A. & Munch, M. Epstein-Barr virus and multiple sclerosis. Epidemiology 11, 220–224 (2000).
Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288–299 (2007).
Alotaibi, S., Kennedy, J., Tellier, R., Stephens, D. & Banwell, B. Epstein–Barr virus in pediatric multiple sclerosis. JAMA 291, 1875–1879 (2004).
Pohl, D. et al. High seroprevalence of Epstein–Barr virus in children with multiple sclerosis. Neurology 67, 2063–2065 (2006).
Banwell, B. et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 6, 773–781 (2007).
Levin, L. I., Munger, K. L., O'Reilly, E. J., Falk, K. I. & Ascherio, A. Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann. Neurol. 67, 824–830 (2010).
Beasley, R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61, 1942–1956 (1988).
Ascherio, A. et al. Epstein–barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083–3088 (2001).
Levin, L. I. et al. Temporal relationship between elevation of Epstein–Barr virus antibody titres and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496–2500 (2005).
Sundström, P. et al. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology 62, 2277–2282 (2004).
DeLorenze, G. N. et al. Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63, 839–844 (2006).
Munger, K. L., Levin, L. I., O'Reilly, E. J., Falk, K. I. & Ascherio, A. Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 17, 1185–1193 (2011).
Simon, K. C., Saghafian-Hedengren, S., Sverremark-Ekström, E., Nilsson, C. & Ascherio, A. Age at Epstein–Barr virus infection and Epstein–Barr virus nuclear antigen-1 antibodies in Swedish children. Mult. Scler. Relat. Disord. 1, 136–138 (2012).
Lünemann, J. D. & Munz, C. EBV in MS: guilty by association? Trends Immunol. 30, 243–248 (2009).
Lovett-Racke, A. E. et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101, 725–730 (1998).
Markovic-Plese, S., Cortese, I., Wandinger, K. P., McFarland, H. F. & Martin, R. CD4+CD28− costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108, 1185–1194 (2001).
Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971–979 (2004).
Lünemann, J. D. et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129, 1493–1506 (2006).
Munz, C. et al. Human CD4+ T lymphocytes consistently respond to the latent Epstein–Barr virus nuclear antigen EBNA1. J. Exp. Med. 191, 1649–1660 (2000).
Lünemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2. J. Exp. Med. 205, 1763–1773 (2008).
Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).
Thorley-Lawson, D. A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1, 75–82 (2001).
Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405–411 (1998).
Pender, M. P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24, 584–588 (2003).
Lassmann, H., Niedobitek, G., Aloisi, F. & Middeldorp, J. M. Epstein–Barr virus in the multiple sclerosis brain: a controversial issue—report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134, 2772–2786 (2011).
Tzartos, J. S. et al. Association of innate immune activation with latent Epstein–Barr virus in active MS lesions. Neurology 78, 15–23 (2012).
Munz, C., Lünemann, J. D., Getts, M. T. & Miller, S. D. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat. Rev. Immunol. 9, 246–258 (2009).
Salmi, A. A., Panelius, M., Halonen, P., Rinne, U. K. & Penttinen, K. Measles virus antibody in cerebrospinal fluids from patients with multiple sclerosis. Br. Med. J. 1, 477–479 (1972).
Vartdal, F., Vandvik, B. & Norrby, E. Viral and bacterial antibody responses in multiple sclerosis. Ann. Neurol. 8, 248–255 (1980).
Derfuss, T., Hohlfeld, R. & Meinl, E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J. Neurol. 252, 986–971 (2005).
Jacobi, C., Lange, P. & Reiber, H. Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J. Neuroimmunol. 187, 139–146 (2007).
Jarius, S. et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 79, 1134–1136 (2008).
Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749–1753 (2007).
Lycke, J. et al. Acyclovir treatment of relapsing–remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J. Neurol. 243, 214–224 (1996).
Friedman, J. E. et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult. Scler. 11, 286–295 (2005).
Lünemann, J. D. et al. Elevated Epstein–Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159–169 (2010).
van der Mei, I. A., Ponsonby, A. L., Blizzard, L. & Dwyer, T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168–174 (2001).
Ebers, G. C. Environmental factors and multiple sclerosis. Lancet Neurol. 7, 268–277 (2008).
Handel, A. E., Giovannoni, G., Ebers, G. C. & Ramagopalan, S. V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 6, 156–166 (2010).
Swank, R. L., Lerstad, O., Strøm, A. & Backer, J. Multiple sclerosis in rural Norway. Its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 246, 721–728 (1952).
Antonovsky, A. et al. Epidemiologic study of multiple sclerosis in Israel. Arch. Neurol. 13, 183–193 (1965).
Cendrowski, W. et al. Epidemiological study of multiple sclerosis in Western Poland. Eur. Neurol. 2, 90–108 (1969).
van der Mei, I. A. et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: a case–control study. BMJ 327, 316–321 (2003).
Kampman, M. T., Wilsgaard, T. & Mellgren, S. I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 254, 471–477 (2007).
Munger, K. L. et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60–65 (2004).
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S. & Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832–2838 (2006).
Lucas, R. M. et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76, 540–548 (2011).
Ascherio, A., Munger, K. L. & Simon, K. C. Vitamin D and multiple sclerosis. Lancet Neurol. 9, 599–612 (2010).
Feskanich, D., Willett, W. C. & Colditz, G. A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am. J. Clin. Nutr. 77, 504–511 (2003).
Hollis, B. W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J. Nutr. 135, 317–322 (2005).
Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T. & Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18–28 (2006).
Yetley, E. A. Assessing the vitamin D status of the US population. Am. J. Clin. Nutr. 88, 558S–564S (2008).
Looker, A. C. et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am. J. Clin. Nutr. 88, 1519–1527 (2008).
Gozdzik, A. et al. Low wintertime vitamin D levels in a sample of healthy young adults of diverse ancestry living in the Toronto area: associations with vitamin D intake and skin pigmentation. BMC Public Health 8, 336 (2008).
Gonzalez-Gross, M. et al. Vitamin D status among adolescents in Europe: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. Br. J. Nutr. 107, 755–764 (2012).
Ascherio, A. & Marrie, R. A. Vitamin D in MS: a vitamin for 4 seasons. Neurology 79, 208–210 (2012).
Lucas, R. M. & Ponsonby, A. L. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation? Prog. Biophys. Mol. Biol. 92, 140–149 (2006).
Sundqvist, E. et al. Confirmation of association between multiple sclerosis and CYP27B1. Eur. J. Hum. Genet. 18, 1349–1352 (2010).
Simon, K. C. et al. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J. Neurol. 258, 1676–1682 (2011).
Wang, J. T. et al. Genetics of vitamin D 1α-hydroxylase deficiency in 17 families. Am. J. Hum. Genet. 63, 1694–1702 (1998).
Torkildsen, Ø., Knappskog, P. M., Nyland, H. I. & Myhr, K. M. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch. Neurol. 65, 809–811 (2008).
Munger, K. L., Chitnis, T. & Ascherio, A. Body size and risk of MS in two cohorts of US women. Neurology 73, 1543–1550 (2009).
Hedström, A. K., Olsson, T. & Alfredsson, L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18, 1334–1336 (2012).
Mirzaei, F. et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann. Neurol. 70, 30–40 (2011).
Willer, C. J. et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330, 120 (2005).
Staples, J., Ponsonby, A. L. & Lim, L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 340, c1640.
Bock, G. et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab. Res. Rev. 27, 942–945 (2011).
Mahon, B. D., Gordon, S. A., Cruz, J., Cosman, F. & Cantorna, M. T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134, 128–132 (2003).
Burton, J. M. et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74, 1852–1859 (2010).
Smolders, J. et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS ONE 5, e15235 (2010).
Jorde, R. et al. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 50, 175–180 (2010).
Schleithoff, S. S. et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83, 754–759 (2006).
Haddad, J. G. & Chyu, K. J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 33, 992–995 (1971).
Better, O. S. et al. in Phosphate and Minerals in Health and Disease (eds Massry, S. G., Ritz, E. & Jahreis, G.) 467–472 (Plenum Press, New York, 1980).
Knippenberg, S. et al. Effect of vitamin D3 supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult. Scler. 17, 1418–1423 (2011).
Peelen, E. et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun. Rev. 10, 733–743 (2011).
Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770–1773 (2006).
Laaksi, I. et al. An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am. J. Clin. Nutr. 86, 714–717 (2007).
Ginde, A. A., Mansbach, J. M. & Camargo, C. A. Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 169, 384–390 (2009).
Andersen, O., Lygner, P. E., Bergström, T., Andersson, M. & Vahlne, A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J. Neurol. 240, 417–422 (1993).
Panitch, H. S. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 36, S25–S28 (1994).
Buljevac, D. et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125, 952–960 (2002).
Nørgaard, M. et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case–control study. Am. J. Epidemiol. 174, 945–948 (2011).
Munger, K. L. et al. Pre-clinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. Am. J. Epidemiol. (in press).
Camargo, C. A. Jr et al. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am. J. Clin. Nutr. 85, 788–795 (2007).
Wallace, R. B. et al. Urinary tract stone occurrence in the Women's Health Initiative randomized clinical trial of calcium and vitamin D supplements. Am. J. Clin. Nutr. 94, 270–277 (2011).
Heaney, R. P., Davies, K. M., Chen, T. C., Holick, M. F. & Barger-Lux, M. J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77, 204–210 (2003).
Vieth, R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am. J. Clin. Nutr. 69, 842–856 (1999).
Ross A. C. et al. for the Institute of Medicine of the National Academies. DRI Dietary Reference Intakes Calcium and Vitamin D (The National Academies Press, Washington, DC, 2011).
Hernán, M. A., Olek, M. J. & Ascherio, A. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 154, 69–74 (2001).
Hernán, M. A. et al. Cigarette smoking and the progression of multiple sclerosis. Brain 128, 1461–1465 (2005).
Villard-Mackintosh, L. & Vessey, M. P. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 47, 161–168 (1993).
Thorogood, M. & Hannaford, P. C. The influence of oral contraceptives on the risk of mulitple sclerosis. Br. J. Obstet. Gynaecol. 105, 1296–1299 (1998).
Hedström, A. K., Bäärnhielm, M., Olsson, T. & Alfredsson, L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 73, 696–701 (2009).
Riise, T., Nortvedt, M. W. & Ascherio, A. Smoking is a risk factor for multiple sclerosis. Neurology 61, 1122–1124 (2003).
Sundström, P., Nyströom, L. & Hallmans, G. Smoke exposure increases the risk for multiple sclerosis. Eur. J. Neurol. 15, 579–583 (2008).
Orton, S. M. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5, 932–936 (2006).
Koch-Henriksen, N. & Sørensen, P. S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9, 520–532 (2010).
Palacios, N., Alonso, A., Bronnum-Hansen, H. & Ascherio, A. Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. Ann. Epidemiol. 21, 536–542 (2011).
Bass, N. H. Pathogenesis of myelin lesions in experimental cyanide encephalopathy. A microchemical study. Neurology 18, 167–177 (1968).
Lessell, S. Experimental cyanide optic neuropathy. Arch. Ophthalmol. 86, 194–204 (1971).
Chen, J. L. et al. Nicotine raises the influx of permeable solutes across the rat blood–brain barrier with little or no capillary recruitment. J. Cereb. Blood Flow Metab. 15, 687–698 (1995).
Sopori, M. L. & Kozak, W. Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 83, 148–156 (1998).
Francus, T., Klein, R. F., Staiano-Coico, L., Becker, C. G. & Siskind, G. W. Effects of tobacco glycoprotein (TGP) on the immune system. II. TGP stimulates the proliferation of human T cells and the differentiation of human B cells into Ig secreting cells. J. Immunol. 140, 1823–1829 (1988).
Rejdak, K. et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63, 1439–1445 (2004).
Simon, K. C. et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 74, 1365–1371 (2010).
De Jager, P. L. et al. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 70, 1113–1118 (2008).
Acknowledgements
This work was funded by grants R01 NS046635, R01 NS073633 and R01 NS071082 from the NIH. The authors thank L. Unger, Harvard School of Public Health, for her technical assistance in preparing this manuscript.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to researching data for the article, providing substantial contribution to discussion of the content, writing the article, and to review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ascherio, A., Munger, K. & Lünemann, J. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 8, 602–612 (2012). https://doi.org/10.1038/nrneurol.2012.198
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.198
This article is cited by
-
Epstein–Barr virus and multiple sclerosis
Nature Reviews Microbiology (2023)
-
Gastrointestinal Tract, Microbiota and Multiple Sclerosis (MS) and the Link Between Gut Microbiota and CNS
Current Microbiology (2023)
-
Effects of perinatal exposure to bisphenol A or S in EAE model of multiple sclerosis
Cell and Tissue Research (2023)
-
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches
Current Allergy and Asthma Reports (2023)
-
Effects of radiation exposure on brain health: a state of the art and new challenges
Environmental Science and Pollution Research (2022)